Chelation Therapy for Rare Earth Element Toxicity: Current Evidence, Challenges, and Future Directions

preprint OA: closed
Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text

This paper reviews the current evidence, challenges, and future directions for chelation therapy used to treat rare earth element toxicity, focusing on how chelators may reduce harmful exposures and what the existing data and practical obstacles are. It summarizes the overall state of evidence rather than reporting new clinical or experimental results, and it highlights limitations such as gaps in comparative data, variability in toxin/chelator context, and the need for better mechanistic and clinical investigation. The paper emphasizes that evidence for chelation in this setting is still evolving and constrained by the challenges of demonstrating efficacy and safety across relevant exposures. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The widespread and growing use of rare earth elements (REE) in modern technologies has raised concerns regarding human exposure and associated toxicological risks through occupational, environmental, and medical pathways, including mining, electronic waste, and gadolinium-based contrast agents in MRI procedures. This review evaluates REE toxicological profiles, focusing on their unique mechanisms, organ-specific effects, and therapeutic challenges. REE toxicity is primarily mediated through oxidative stress, mitochondrial dysfunction, and metal ion substitution, leading to multi-organ effects, impacting respiratory, cardiovascular, nervous, hepatic, and reproductive systems. Studies in human clinical data, animal models (e.g., rats, mice, zebrafish), and in vitro systems show adverse effects, although dose-specific data remain limited, with examples including gadolinium retention post-MRI and cerium exposure in occupational settings. Conventional chelators such as EDTA, DMSA, and DMPS demonstrate limited efficacy against most REE, with DTPA showing moderate potential particularly for gadolinium and cerium. Evidence from occupational studies, animal experiments, and clinical reports highlights the need for early exposure recognition, prevention, and individualized treatment strategies, including supportive care and REE-specific chelation when feasible. The absence of targeted regulatory frameworks and comprehensive clinical data hinders effective risk management. Future research priorities include developing novel REE-specific chelators, establishing evidence-based therapeutic protocols, and harmonizing international regulations. This review provides healthcare professionals, toxicologists, and researchers with an updated synthesis of current knowledge on REE toxicity and therapeutic strategies, emphasizing the urgent need for clinical innovation and regulatory reform to address this emerging public health concern.
Full text 621 characters · extracted from oa-doi-fallback · click to expand
There is a newer version available for this {{ publicationType }}. View latest version {{ publication.field_name }} {{ publication.subfield_name }} Copyright: © {{ publicationYear }} {{ publication.presentation_authors[0].full_name + (publication.presentation_authors.length > 1 ? ' et al' : '') }}. This is an open access publication distributed under the terms of the CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Check the {{ publicationType | capitalize }} Source for copyright and license information. Listen on

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00